RightRep EN · PT Open the app
BLOG

Does Smoking Kill Gains? Should You Quit to Build Muscle? (What the Research Says)

By RightRep AI Assistant · · 15 min read

Every gym has one: the lifter who trains hard, eats right, sleeps eight hours — and then walks out the side door for a cigarette, as if the two habits live in different universes. The rest of the internet's fitness culture talks about smoking like it's a gains holocaust; the tobacco industry's own legacy studies once claimed athletes smoked "for digestion." Does smoking actually kill gains — and is it worth quitting if muscle is the goal?

The honest answer has more shape than either camp allows. Smoking does not press an off-switch on hypertrophy — plenty of smokers build muscle, and some of the scariest numbers in the literature come from sixty-something chain smokers, not gym-goers in their twenties. But the machinery that builds and keeps muscle runs measurably worse in smokers: the cellular rate at which muscle protein is made, the amount of lean mass people carry into old age, the power and oxygen systems that fuel training, and the healing of the tendons lifting depends on. Meanwhile the field's most counterintuitive finding — smokers' testosterone runs higher, not lower — is true, and much less useful than it sounds. And vaping, the thing lifters actually ask about now, is nicotine without most of the smoke: acutely it barely dents a workout, chronically the warning lights are already blinking, and the muscle-specific evidence barely exists. Every number below was read directly from the source abstracts — the studies are listed at the end.

The short answer: it taxes the machinery, not the on-switch

Four verdicts up front. On muscle building itself: smoking slows the muscle-protein synthesis process — in the one direct human measurement, by roughly a third — and turns up the genetic signals for muscle breakdown [1]. On the long game: smokers carry less lean mass as they age and run a modestly higher risk of sarcopenia [3][4]. On performance: in young, active, light smokers (about a dozen cigarettes a day), peak oxygen uptake ran 8% lower, peak power 11% lower, and recovery after exhaustion was visibly slower [2] — though the older VO₂max literature is genuinely split [6], which we'll read honestly. On the one thing everyone gets wrong: smoking is associated with higher testosterone in men [5] — via slower clearance, not more production — so the "smoking kills your T" story is false, and the damage lives somewhere else entirely. Vaping gets its own honest section: acute nicotine mostly moves blood pressure [7], regular vaping shows early fitness reductions in the young [8], and the muscle question is literally still at the review-protocol stage [9].

What smoke does to the build machinery

The single most direct study ever done on this question took eight smokers — at least 20 cigarettes a day for at least 20 years — and eight matched non-smokers, infused stable-isotope leucine, and measured the fractional synthesis rate of muscle protein directly in thigh muscle biopsies [1]. The smokers' muscle was building protein at 0.037 ± 0.005 %/h against the non-smokers' 0.059 ± 0.005 %/h — about 37% slower (P = 0.004) [1]. Same plasma leucine, same whole-body protein breakdown, same inflammation markers: the fuel was arriving; the factory was running at two-thirds speed. And the gene expression told the same story from the other side — myostatin (the muscle-growth brake) up ~33%, and MAFbx (an E3 ubiquitin ligase — the proteasome's "tear this down" tag) up ~45%, while MuRF-1, its sibling, didn't move [1]. Slower build, louder demolition signal.

Two honest footnotes belong on that study. First, the subjects were around 65 years old, lifetime heavy smokers — this is the worst case, not the average gym member who smokes five a day at 25. Second, it's one trial, eight per arm, never (to our knowledge) repeated in young trainees — treat it as the clearest window we have, not a precisely priced tax. But its direction is exactly what the population data predicts, which is why it got famous: muscle that synthesizes protein 37% slower, with myostatin dialed up, is muscle that grows less from the same training volume and protein intake — the same arithmetic that makes sleep and alcohol lifters' business.

The lean-mass ledger: what smokers carry into old age

Cross-sectional biology is one thing; what people actually carry is another. The MINOS cohort put 845 men aged 45–85 through dual-energy X-ray absorptiometry and found current smokers carried 3.2% less appendicular (limb) muscle mass than never-smokers (P < 0.003) — for perspective, men who exercised regularly in leisure time carried only 2.2% more than sedentary men [3]. The men in the lowest muscle-mass quartile smoked more, weighed less, and moved less [3]. Meta-analytically, twelve studies and 22,515 participants put smoking's isolated sarcopenia risk at OR 1.12 (95% CI 1.03–1.21) overall, 1.20 (1.06–1.35) in men — real, modest, and built from wildly inconsistent individual studies, which the authors say plainly [4].

So: not a cataclysm, a drift. A few percent of muscle mass, a small odds-ratio bump in frailty risk — the kind of tax you don't notice at 25 and pay with interest at 65, which is the exact wrong trade for lifters, whose strength-carrying-into-old-age project is the longest game in the gym. It also rhymes with the detraining ledger: muscle is always being built and demolished simultaneously, and smoking nudges both dials the wrong way at once [1].

The performance tax: what it does to the session itself

Here the best new evidence lands uncomfortably close to home, because it studied young, physically active smokers — 22-year-olds, about 12 cigarettes a day for six years, normal lung volumes, matched training habits with non-smoking peers [2]. On an exhaustive incremental cycle test, the smokers' static lung function looked fine, but their peak expiratory flow was 23% lower, maximal voluntary ventilation 10% lower, VO₂peak 8% lower, peak mechanical power 11% lower, and both ventilatory and lactate thresholds arrived at lower work rates (ventilatory P < 0.01, lactate P = 0.01) [2]. Recovery told the same story: the time constant of oxygen-recovery kinetics was 52% slower, and heart rate recovered 31% less in the first 30 seconds after exhaustion [2].

For lifters, read that recovery line twice. Between-set recovery — the ability to bring the next set to a high effort — is where oxygen kinetics and heart-rate recovery live, and it's precisely what high-rep sets, supersets and metabolic work tax. A smoker's engine spools down slower after every hard effort. The honest counterweight: a systematic review of the older VO₂max literature found half the studies showed significantly lower maxima in smokers, half showed no significant difference [6] — light smoking in the young is not COPD, and the fitness literature is noisier than the protein-synthesis literature. The fair summary is the Milan study's own: this is early impairment in people with a relatively short smoking history [2] — a tax that starts small and compounds.

The testosterone twist — the field's most misused fact

Now the part every gym forum gets backwards. Across 22 studies and 13,317 men, smokers' mean testosterone ran 1.53 nmol/L higher than non-smokers' (95% CI 1.11–1.96) — a small but consistent elevation, with no clear association in women (0.11 nmol/L, CI −0.08 to 0.30) [5]. Before anyone lights a "T-boosting" cigarette: the proposed mechanism is that cotinine, a nicotine metabolite, inhibits testosterone breakdown — smokers' testosterone lingers longer because clearance slows, not because their bodies make more [5]. Higher circulation, slower drain.

And the ledger above is the proof of how little that buys: men with higher circulating testosterone and 3% less limb muscle [3], muscle building protein 37% slower [1], myostatin — testosterone's downstream adversary — turned up [1]. Hormones are signals; muscle is machinery that responds to them. Smoking raises the signal and degrades the receiver. It's the same lesson as the post-workout testosterone spike: the men who spiked hardest grew no more, because transient hormone differences are not the lever the magazine rack claims. If your T is clinically low, that's a doctor's conversation — not a cigarette.

Healing: the injured-lifter angle nobody prices in

Lifters tear things — tendons mostly, sometimes badly enough to need surgery. Here smoking's tax is the steepest in the whole file. A meta-analysis of 14 studies and 73,817 rotator-cuff-repair patients found smoking raised the risk of structural re-tear by 2.06× (95% CI 1.30–3.28) and re-operation by 1.29× (1.20–1.40) [10] — and, in the review's own honest detail, patients' pain scores were mostly similar between smokers and non-smokers; the structural repair itself is what failed [10]. The mechanism has been demonstrated experimentally: in a rat rotator-cuff model, nicotine delivery prolonged inflammation, cut cell proliferation and collagen-I expression at the repair site, and left the attachment mechanically weaker at day 10 and day 28 — the gap only closing by day 56 [11].

That last number is the one to sit with: nicotine didn't stop healing, it delayed it, and in surgery the early weeks are when the repair is most fragile. If you're a lifter heading into any tendon repair — shoulder, knee, Achilles — the smoking question is no longer about gains; it's about whether the surgery works.

The cautionary tail: where the road ends

Every condition above was "healthy smokers, early tax." The end-state of the same road is COPD, and its muscle chapter is the starkest in respiratory medicine: cachexia and muscle wasting are common features of the disease, they adversely affect prognosis, and — the detail that keeps it from being a eulogy — they are partly reversible, which is why muscle maintenance is now integrated into COPD care itself [13]. Nobody who squats today plans to be there. The point of including it is simpler: the muscle-wasting effects of smoking are not a gym myth invented by personal trainers; they're a recognized clinical entity with its own literature, and the early version of that same biology is what the studies above catch in healthy smokers [1][3].

Vaping: nicotine without the smoke — and almost without evidence

Lifters don't ask about cigarettes anymore; they ask about vape. The honest answer has three layers. Acute: in a double-blind trial, 20 non-users vaped 18 mg of nicotine or placebo — resting diastolic blood pressure rose ~3 mmHg, exercise blood pressure ran higher, and… that was it: metabolic rate, VO₂peak and peak wattage were statistically unchanged [7]. One acute vape session does not ruin a workout. Chronic: the first well-controlled comparison took 26 young regular vapers (about four years of use) against matched non-users and found lower VO₂peak — even after controlling for fat-free mass and lean body mass — along with blunted heart-rate response to exercise and impaired skeletal-muscle oxygen utilization [8]. Different group, same conclusion: young, "apparently healthy," early warning lights [8]. The muscle question itself: does vaping impair hypertrophy, or MPS, like smoking does [1]? Nobody knows — the systematic review that would begin to answer it is, as of 2025, a published protocol still waiting for its data [9]. The testosterone review's authors flag the same hole: cotinine slows testosterone clearance [5], vapers run cotinine [7], and the long-term picture is unstudied.

So the vaping verdict writes itself: less harmful than smoking is a low bar, "no carbon monoxide" does not mean "no tax," the early fitness signals are negative [8], and anyone claiming to know what decades of vaping does to muscle growth is selling something. The nicotine itself is the agent your recovery systems have to negotiate with — the dose is lower, the smoke is gone, and the certainty is gone with it.

Quitting: the weight-gain fear, answered with numbers

The single reason lifters give for not quitting — "I'll get fat and lose my abs" — has the best-priced evidence in this whole guide. Across 62 studies, untreated quitters gained a mean of 1.12, 2.26, 2.85, 4.23 and 4.67 kg at 1, 2, 3, 6 and 12 months — most of it inside the first three months [12]. But the distribution is the real story: 16% of quitters lost weight, 37% gained under 5 kg, 34% gained 5–10 kg, and 13% gained more than 10 kg [12]. Pharmacotherapy didn't change the numbers, and — notably for gym people — neither did being especially worried about weight gain [12].

Now put that in lifter currency. Four to five kilograms over a year is roughly one modest lean-bulk of scale weight, arriving while the machinery that builds muscle — synthesis rate, oxygen delivery, tendon healing — is un-taxing itself [1][2][10]. Weight is not muscle (recomp 101); a training population managing protein targets and volume can steer that gain, and the 16% who lose weight are mostly people who replaced the habit with… movement. This is evidence-reading, not a quit program: cessation is a medical process with real pharmacology and real support lines, and the quit conversation belongs with a clinician or your country's public-health service — this guide's job is only to say the muscle excuse doesn't survive the numbers.

How RightRep fits into this

Everything smoking taxes is something a ledger can see before you can:

  • You cannot feel a 37% slower synthesis rate [1] — you can see the rep score that doesn't climb this mesocycle the way the last one did. Reps counted from the camera turn "am I actually progressing?" into data instead of vibes.
  • Recovery between efforts is the smoker's most measurable session tax [2] — same loads, longer gaps, fewer good sets. Camera-counted reps make the set ledger honest about it.
  • The "why am I not growing" checklist just gained a line. Sleep, protein, volume, progression — the standard audit in that guide — assumes the machinery is healthy. Smoking is the one variable that degrades all four lanes at once while feeling like a lifestyle choice.
  • Track the training, not the vice. The same honest-ledger argument as RightRep vs Hevy and RightRep vs Fitbod: whatever you decide about nicotine, the decision gets made better with a year of real training data behind it.

The bottom line

Does smoking kill gains? Not instantly, and not totally — but it runs a measurable tax on every floor of the building: muscle protein synthesis ~37% slower with demolition signals up in heavy smokers [1], ~3% less limb muscle mass and a 1.2× sarcopenia odds bump in the long ledger [3][4], 8–11% off peak power and oxygen uptake with visibly slower recovery even in young light smokers [2], and re-tear risk doubled after tendon surgery [10] — while the "low T" story turns out backwards [5] and vaping sits in the early-warnings-and-unknowns band [7][8][9]. Should you quit to build muscle? The weight-gain fear is a 4–5 kg mean that a training population can steer [12], and everything on the taxed list starts un-taxing the day you do. Either way, keep the ledger: rightrep.app counts the reps so the trend line tells the truth.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Petersen AMW, Magkos F, Atherton P, Selby A, Smith K, Rennie MJ, Pedersen BK, Mittendorfer B. Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle. American Journal of Physiology-Endocrinology and Metabolism, 2007;293(3). pubmed.ncbi.nlm.nih.gov
  2. Borrelli M, Doria C, Toninelli N, Longo S, Coratella G, Cè E, Rampichini S, Esposito F. Cigarette Smoking Impairs Cardiorespiratory and Metabolic Response at Peak Incremental Exercise and during Recovery in Young, Physically Active Adults. Medicine & Science in Sports & Exercise, 2025;57(4). pubmed.ncbi.nlm.nih.gov
  3. Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. American Journal of Clinical Nutrition, 2004;80(2). pubmed.ncbi.nlm.nih.gov
  4. Steffl M, Bohannon RW, Petr M, Kohlikova E, Holmerova I. Relation between cigarette smoking and sarcopenia: meta-analysis. Physiological Research, 2015;64(3). pubmed.ncbi.nlm.nih.gov
  5. Zhao J, Leung JYY, Lin SL, Schooling CM. Cigarette smoking and testosterone in men and women: A systematic review and meta-analysis of observational studies. Preventive Medicine, 2016;85. pubmed.ncbi.nlm.nih.gov
  6. Sengbusch JR, Tiernan DL, Tamulevicius N, Martinasek MP. The Impact of Smoking on Maximum Oxygen Uptake. Respiratory Care, 2021;66(5). pubmed.ncbi.nlm.nih.gov
  7. Fogt DL, Levi MA, Rickards CA, Stelly SP, Cooke WH. Effects of Acute Vaporized Nicotine in Non-Tobacco Users at Rest and during Exercise. International Journal of Exercise Science, 2016;9(5). pubmed.ncbi.nlm.nih.gov
  8. Simovic T, Matheson C, Cobb K, Heefner A, Thode C, Colon M, Tunon E, Billingsley H, Salmons H, Ahmed SI, Carbone S, Garten R, Breland A, Cobb CO, Nana-Sinkam P, Rodriguez-Miguelez P. Young users of electronic cigarettes exhibit reduced cardiorespiratory fitness. Journal of Applied Physiology, 2024;137(3). pubmed.ncbi.nlm.nih.gov
  9. Thode H, Heshmati J, Mir H. Association between e-cigarette use, physical activity and cardiorespiratory fitness: protocol for a systematic review. BMJ Open, 2025;15(7). pubmed.ncbi.nlm.nih.gov
  10. Fan N, Yuan S, Du P, Wu Q, Li J, Kong X, Zhu W, Hong G, Zang L. The effects of smoking on clinical and structural outcomes after rotator cuff repair: a systematic review and meta-analysis. Journal of Shoulder and Elbow Surgery, 2022;31(3). pubmed.ncbi.nlm.nih.gov
  11. Galatz LM, Silva MJ, Rothermich SY, Zaegel MA, Havlioglu N, Thomopoulos S. Nicotine delays tendon-to-bone healing in a rat shoulder model. Journal of Bone and Joint Surgery (American), 2006;88(9). pubmed.ncbi.nlm.nih.gov
  12. Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ, 2012;345:e4439. pubmed.ncbi.nlm.nih.gov
  13. Sanders KJ, Kneppers AE, van de Bool C, Langen RC, Schols AM. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. Journal of Cachexia, Sarcopenia and Muscle, 2016;7(1). pubmed.ncbi.nlm.nih.gov